May 7th 2024
Following treatment, 17.5% and 13% of patients reported residual depressive and anxiety symptoms.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Study: How Can Digital Therapeutic Interventions Improve Symptoms of Atopic Dermatitis?
April 12th 2022What role will digital therapeutic agents have in the coming years of atopic dermatitis treatment? It’s still being studied, but Jonathan Silverberg, MD, reviewed an interventional study that may provide key insights into what’s to come.
The Burden of Itch for Pediatric Patients and Parents
April 12th 2022Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research, explores the hidden burdens of itch that many pediatric patients and parents have to deal with on a daily basis. She expanded on her talk from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference was held from April 9 to 11 in Baltimore, Maryland
Dupilumab's Impact on Quality of Life in Children 6 Months to 5 Years
April 11th 2022An abstract presented at the Revolutionizing Atopic Dermatitis conference discussed the impact of treatment with dupilumab on quality of life for children aged 6 months to 5 years with atopic dermatitis, as well as their caregivers.
Available Atopic Dermatitis Therapies for Pediatric Patients
April 10th 2022Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, expands on his AD overview from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference is being held from April 9 to 11 in Baltimore, Maryland.
Translating Evidence into Practice: Atopic Dermatitis Guidelines
March 26th 2022In their session, “Translating Evidence into Practice: Atopic Dermatitis Guidelines,” at the current AAD annual meeting, Jonathan I. Silverberg, MD, PhD, MPH, FAAD, Peter A. Lio, MD, FAAD, Andrew Blauvelt, MD, FAAD, and Robert Sidbury, MD, MPH, FAAD, discuss updates in new therapies, clinical pearls, and potential co-morbidities.
Future Directions for Dupilumab in Atopic Dermatitis Management
March 24th 2022An expert dermatologist evaluates the role of dupilumab in decreasing the clinical burden of severe atopic dermatitis on patients and their caregivers and shares insight on the future outlook of dupilumab in disease management.